Rockville, MD, Jan. 30, 2025 (GLOBE NEWSWIRE) — The humanized mice model market is estimated to be US$ 101.6 million in 2024. The market is projected to expand at a CAGR of 6.0%, reaching a valuation of US$ 182.0 million by 2034.
The humanized mice model market is driven by the rising usage in the identification of immunodeficiency disorders, cancers, and other rare diseases. Increasing research and development activities carried out by pharmaceutical & biotechnology companies are fueling the market growth.
Continuous support and initiatives from governments for research and growth in the adoption of modified medicine are further increasing the demand for humanized mice models. The market is expected to be driven by factors such as the increasing acceptance of tailored medications, the growing prevalence of cancer, and technological improvements.
Stringent regulations and laws formulated for the ethical use of animals and costly procedures for the maintenance of animal housing restrain the growth of the market. Increased production of monoclonal antibodies and healthcare improvement in developing nations are expected to provide growth opportunities for the market.
For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9627
Key Takeaways from the Humanized Mice Model Market Study
- Based on model type, the cell-based segment is projected to surge at a CAGR of 6.1% by 2034.
- Based on application, the oncology segment is expected to rise 6.2% CAGR by 2034.
- The United States humanized mice model market is estimated to surge at a 5.9% CAGR by 2034.
- China’s humanized mice model market is projected to expand at a CAGR of 6.7% by 2034.
- The global humanized mice model market is expected to reach a valuation of US$ 182.0 million in 2034.
“The market for humanized mice models is expected to rise due to the growing need for individualized medications created utilizing animal models, particularly mice. Immunodeficiency models are filled with transplanted human tissues and illness symptoms to determine the best course of action. This increases the variables affecting the worldwide market by giving the patient access to appropriate or personalized medications,” says a lead Fact. MR analyst.
Competitive Landscape
Key players in the humanized mice model market include THE JACKSON LABORATORY, laconic Biosciences, Inc., Genoway S.A., Yecuris Corporation, Charles River Laboratories, Inc., Crown Bioscience Inc., Ingenious Targeting Laboratory Inc., orizon Discovery Group plc, HuMurine Technologies, and Trans Genic Inc., Ltd.
The competitive landscape in the market for humanized mouse models is dynamic and diverse. Top corporations are concentrating on research & development, sustainable sourcing, and innovative formulas to improve their market presence.
Leading companies are strongly emphasizing product certifications, ecologically friendly operations, and meeting the growing demand for personalized medications. Market leaders are maintaining their positions and profiting from the increasing demand by concentrating on product quality and innovation.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9627
For instance,
- In October 2021, the non-profit biomedical research organization, The Jackson Laboratory (JAX) in the United States, acquired Charles River Laboratories Japan’s Research Models & Services (RMS) division as a wholly-owned subsidiary.
- In February 2019, H.I.G. Capital LLC, through one of its affiliates, acquired Taconic Biosciences Inc.
Humanized Mice Model Industry News:
- The Research Models & Services (RMS) section of Charles River Laboratories Japan was purchased by The Jackson Laboratory (JAX), a non-profit biomedical research organisation in the United States, as a wholly-owned subsidiary in October 2021.
- Taconic Biosciences Inc. was purchased by H.I.G. Capital LLC through one of its affiliates in February 2019.
- In order to increase the timeliness and accessibility of high-quality research models and services in China, The Jackson Laboratory and Beijing Anitec Biotechnology established a joint venture collaboration in November 2020.
Check out More Related Studies Published by Fact.MR Research:
Newly-released vaccine adjuvants market analysis report by Fact.MR reveals that global sales of the Vaccine Adjuvants in 2022 were held at US$ 1.9 Billion. With 12.3% projected growth from 2023 to 2033, the market is expected to reach a valuation of US$ 6.8 Billion by the end of the forecast period.
The value of the global cell line development market stands at US$ 4.97 billion in 2023 and is projected to reach a valuation of US$ 8.2 billion by the end of 2033. Over the next ten years, Fact.MR’s research projects global demand for cell line development to rise at 5.1% CAGR.
Newly released data by Fact.MR, a market research and competitive intelligence provider, reveals that the global monoclonal antibodies market size is valued at US$ 228.99 billion in 2023 and is forecasted to reach US$ 692.39 billion, expanding swiftly at a CAGR of 11.7% through 2033.
The global gene delivery systems market currently accounts for a valuation of US$ 3 billion and is expected to reach US$ 4.1 billion by the end of 2027. Global demand for gene delivery systems is predicted to magnify at a CAGR of 6.5% from 2022 to 2027.
The global gene therapy market size is calculated at a value of US$ 10.34 billion in 2024. Increasing cases of rare diseases is contributing to the rising need for cell and gene therapies. Expanding at a CAGR of 14.1%, the market is forecasted to reach US$ 38.52 billion by the end of 2034.
About Us:
Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.
With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay competitive.
Contact:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
